Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent ...

For DeepTech funder Cambridge Innovation Capital, it’s a case of back to the future after its decision to take venture ...

Synthetic biology specialist GRO Biosciences is exploring strategic alternatives about six months after raising a series B ...

X-linked severe combined immunodeficiency disease (X-SCID) is a rare genetic disorder characterized by profound defects in ...

TRIMTECH Therapeutics’s incredible $31million seed funding haul will be deployed to develop treatments for severe ...

Alltrna’s CEO Michelle Warner said that the approach allows for basket trials that can group patients with different diseases ...

Trimtech Therapeutics has closed a seed funding round of $31m (£25m) to advance its pipeline of CNS penetrant therapeutics.

X-linked severe combined immunodeficiency disease (X-SCID) is a rare genetic disorder characterized by profound defects in T-cell, B-cell, and natural ...

The team was able to reach protein yields at the pool stage that couldn’t be achieved previously with a random integration approach.

Peptides designed by artificial intelligence restrict both drug-resistant bacteria and rapidly evolving viruses.

Mary Berry’s simple recipe calls for just three ingredients ― egg, milk, and flour, along with a little oil.

TRIMTECH Therapeutics raises $31M to enhance its TRIMTAC platform, targeting protein aggregates in neurodegenerative diseases for improved therapeutic outcomes.